Redeye comments on Cantargia's third quarter report 2025.
Redeye strengthens its positive view of Formpipe following the Q3 report, showing a rebound in ACV a...
Endomines announced the sale of three of its gold deposits in Idaho.
* Strong NOI margin behind rec. PTP +1% vs ABGSCe * Cons to raise estimates (rec.
Redeye provides a short comment on the technology evaluation agreement with SeeQ Diagnostics.
Ahead of the Q3 report, we make only minor changes to our estimates but lift 2026E-27E EBITDA by 1-2...
* Q3 was a step back, but 2026e should recover * We cut adj.
Today, Binero announced its acquisition of Hibox amounting to SEK75m, at multiples of 11x EBIT and 6...
Xbrane today provided an update on the expected timeline for the resubmission of the BLA for its ran...
Cell Impact verkar fortsatt i en mycket utmanande marknad där både bränslecells- och elektrolyssegme...
Redeye comments on Formpipe’s Q3, showing ARR growth and EBITDA-CAPEX in line with our expectations.
* Q3 fairly in line, EBIT adj. SEK -69m (consensus -62m) * Savings program initiated, annual savings...
Redeye comments on Mendus announcing a directed share issue.
Redeye returns with an updated view following Nekkar’s soft Q3 figures driven by Syncrolift, while F...
Redeye adjusts its estimates and fair value range following Arise’s Q3 report.
